• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc. (Amendment)

    2/14/24 3:58:11 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARQT alert in real time by email
    SC 13G/A 1 arcu.htm 13G HTML File DOCUMENT TYPE SC 13G/A
    TEXT


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    Amendment # 1

    Name of Issuer: ARCUTIS BIOTHERAPEUTICS INC
    _____________________________________________________
    Title of Class
    of Securities: Common Stock

    CUSIP Number: 03969K108

    1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON

    Prudential Financial, Inc. 22-3703799

    2.) MEMBER OF A GROUP: (a) N/A
    (b) N/A

    3) SEC USE ONLY:



    4) PLACE OF ORGANIZATION: New Jersey

    NUMBER OF SHARES BENEFICIALLY OWNED BY REPORTING PERSON WITH:

    5) Sole Voting Power: 222,638 See Exhibit A
    6) Shared Voting Power: 9,661,499 See Exhibit A
    7) Sole Dispositive Power: 222,638 See Exhibit A
    8) Shared Dispositive Power: 9,661,499 See Exhibit A

    9) AGGREGATE AMOUNT BENEFICIALLY OWNED: 9,884,137 See Exhibit A

    10) AGGREGATE AMOUNT IN ROW (9) EXCLUDES SHARES: Not applicable

    11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 10.47 See Exhibit A

    12) TYPE OF REPORTING PERSON: HC

    ITEM 1(a). NAME OF ISSUER:

    ARCUTIS BIOTHERAPEUTICS INC

    ITEM 1(b). ADDRESS OF ISSUER'S EXECUTIVE OFFICES:

    3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE, CA 91361

    ITEM 2(a). NAME OF PERSON FILING:

    Prudential Financial, Inc.

    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:

    751 Broad Street
    Newark, New Jersey 07102-3777

    ITEM 2(c). CITIZENSHIP:

    New Jersey

    ITEM 2(d). TITLE OF CLASS OF SECURITIES:

    Common Stock

    ITEM 2(e). CUSIP NUMBER:

    03969K108

    ITEM 3. The Person filing this statement is a Parent Holding Company as
    defined in Section 240.13d-1(b)(1)(ii)(G) of the Securities Exchange
    Act of 1934.

    ITEM 4. OWNERSHIP:

    (a) Number of Shares
    Beneficially Owned: 9,884,137 See Exhibit A


    (b) Percent of Class: 10.47


    (c) Powers                No. Of Shares
    ----------- --------------------
    Sole power to vote or 222,638 See Exhibit A to direct the vote
    Shared power to vote or 9,661,499 See Exhibit A to direct the vote
    Sole power to dispose or 222,638 See Exhibit A to direct disposition
    Shared power to dispose 9,661,499 See Exhibit A or to direct disposition

    ITEM 5. OWNERSHIP OF 5% OR LESS OF A CLASS:

    Not Applicable

    ITEM 6. OWNERSHIP OF MORE THAN 5% ON BEHALF OF
    ANOTHER PERSON:

    Our clients may have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities which are the subject of this filing.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE
    SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING
    REPORTED ON BY THE ULTIMATE PARENT COMPANY:

    See Exhibit A

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF
    MEMBERS OF THE GROUP:

    Not Applicable

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

    Not Applicable

    ITEM 10. CERTIFICATION:

    By signing below, Prudential Financial, Inc. certifies that, to the best of its
    knowledge and belief, the securities referred to above were acquired
    and are held in the ordinary course of business and were not acquired
    and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired
    and are not held in connection with or as a participant in any transaction
    having that purpose or effect.


    The filing of this statement should not be construed as an admission that
    Prudential Financial, Inc. is, for purposes of Sections 13 or 16 of the Securities
    Exchange Act of 1934, the beneficial owner of such shares.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief,
    Prudential Financial, Inc. certifies that the information set forth in this
    statement is true, complete and correct.

    PRUDENTIAL FINANCIAL, INC.

    By:RICHARD BAKER
    Second Vice President

    Date:2-14-2024
    As of:12-31-2023

    Exhibit A
    --------------

    ITEM 4. OWNERSHIP:

      Through its parent/subsidiary relationship, Prudential Financial, Inc. may
      be deemed the beneficial owner of the same securities as the Item 7 listed
      subsidiaries and may have direct or indirect voting and/or investment
      discretion over 9,884,137 shares.
      

    These shares were acquired in the ordinary course of business, and not with the purpose or effect of changing or influencing control of the Issuer. The filing of this statement should not be construed as an admission that Prudential Financial, Inc. is, for the purposes of Sections 13 or 16 of the Securities Exchange Act of 1934, the beneficial owner of these shares.




    ITEM 7. IDENTIFICATION/CLASSIFICATION:

    Prudential Financial, Inc. is a Parent Holding Company and the indirect parent of the following subsidiaries, who are the beneficial owners of the number and percentage of securities which are the subject of this filing as set forth next to their names:
    

    
    
    Subsidiaries Number of Shares Percentage
    The Prudential Insurance Company of America IC 0 0.00
    Jennison Associates LLC IA 9,066,082 9.61
    PGIM, Inc. IA 730,000 0.77
    PGIM Quantitative Solutions LLC IA 88,055 0.09
    PRUCO Securities, LLC IA 0 0.00





    Get the next $ARQT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARQT

    DatePrice TargetRatingAnalyst
    7/25/2025$18.00Neutral
    Goldman
    12/30/2024$19.00Buy
    H.C. Wainwright
    8/28/2024$15.00Buy
    Jefferies
    1/3/2024$4.00 → $8.00Neutral → Buy
    Mizuho
    10/26/2023$57.00 → $4.00Buy → Neutral
    Mizuho
    10/13/2023$32.00 → $6.00Buy → Neutral
    Goldman
    9/7/2022$46.00Buy
    Needham
    3/17/2022$45.00Buy
    Goldman
    More analyst ratings

    $ARQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peetz Christopher was granted 4,315 shares (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    7/17/26 4:07:34 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Peetz Christopher claimed ownership of 187,500 shares (SEC Form 3)

    3 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    7/17/26 4:04:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Welgus Howard G. exercised 4,096 shares at a strike of $7.93 and sold $127,284 worth of shares (4,730 units at $26.91) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 37,109 units (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    7/17/26 4:01:26 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/17/25 5:45:01 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $30,247 worth of shares (2,268 units at $13.34) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/6/25 8:44:37 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $68,821 worth of shares (5,040 units at $13.65) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    5/23/25 4:04:50 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ARQT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ARQT
    SEC Filings

    View All

    Goldman initiated coverage on Arcutis Biotherapeutics with a new price target

    Goldman initiated coverage of Arcutis Biotherapeutics with a rating of Neutral and set a new price target of $18.00

    7/25/25 9:06:04 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Arcutis Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $19.00

    12/30/24 7:23:09 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Arcutis Biotherapeutics with a new price target

    Jefferies initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $15.00

    8/28/24 7:20:44 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)

    7/16/26 4:25:02 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)

    6/9/26 4:05:26 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Arcutis Biotherapeutics Inc.

    SCHEDULE 13G - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    5/12/26 9:55:12 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcutis Expands Board of Directors with Appointment of Chris Peetz

    WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Christopher "Chris" Peetz has been appointed to the Arcutis Board of Directors effective July 15, 2026.  "We are delighted to welcome Chris Peetz to our Board of Directors at a pivotal time for Arcutis," said Frank Watanabe, president and chief executive officer of Arcutis. "Chris has built an impressive track record leading biopharmaceutical companies through periods of expansion, from advancing multiple products through development, to building commerci

    7/16/26 9:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

    WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its second quarter 2026 financial results and provide a business update after the U.S. financial markets close on Wednesday, August 5, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET that same day. A live webcast of the call and related presentation materials will be available on the "Events" section of the Company’s website. A replay of the webcast will be available on the Arcutis investor website following the c

    7/15/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Attovia Therapeutics Appoints John W. Smither to Board of Directors

    SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the appointment of John W. Smither to its Board of Directors as an independent director and as Chair of the Audit Committee. "We are pleased to welcome John to our Board," said Tao Fu, Founder and Chief Executive Officer of Attovia. "John is a proven leader in guiding biotechnology companies through critical stages of development. Having served as Chief Financial Officer across multiple public and private biotechnology companies,

    7/15/26 8:30:00 AM ET
    $MBX
    $ARQT
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Financials

    Live finance-specific insights

    View All

    Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

    WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its second quarter 2026 financial results and provide a business update after the U.S. financial markets close on Wednesday, August 5, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET that same day. A live webcast of the call and related presentation materials will be available on the "Events" section of the Company’s website. A replay of the webcast will be available on the Arcutis investor website following the c

    7/15/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

    Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025Continued strong demand for ZORYVE despite typical Q1 seasonality, with continued growth in share of branded non-steroidal topical treatmentsSubmitted supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to the U.S. Food and Drug Administration (FDA) to expand the indication for the treatment of atopic dermatitis in infants ages 3 to 24 monthsCompleted enrollment in ZORYVE foam 0.3% Maximum Usage Systemic Exposure (MUSE) trial in children with plaque psoriasis of the scalp and body ages 2 to 11 yearsInitiated Phase 1a/1b, first-in-huma

    5/6/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

    WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30pm ET. A live webcast of the call and related presentation materials will be available on the "Events" section of the Company's website. A replay of the webcast will be available on the Arcutis investor website following the conferen

    4/15/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/13/24 4:30:25 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/6/24 4:00:53 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    Leadership Updates

    Live Leadership Updates

    View All

    Arcutis Expands Board of Directors with Appointment of Chris Peetz

    WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Christopher "Chris" Peetz has been appointed to the Arcutis Board of Directors effective July 15, 2026.  "We are delighted to welcome Chris Peetz to our Board of Directors at a pivotal time for Arcutis," said Frank Watanabe, president and chief executive officer of Arcutis. "Chris has built an impressive track record leading biopharmaceutical companies through periods of expansion, from advancing multiple products through development, to building commerci

    7/16/26 9:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Attovia Therapeutics Appoints John W. Smither to Board of Directors

    SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the appointment of John W. Smither to its Board of Directors as an independent director and as Chair of the Audit Committee. "We are pleased to welcome John to our Board," said Tao Fu, Founder and Chief Executive Officer of Attovia. "John is a proven leader in guiding biotechnology companies through critical stages of development. Having served as Chief Financial Officer across multiple public and private biotechnology companies,

    7/15/26 8:30:00 AM ET
    $MBX
    $ARQT
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

    Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (NASDAQ:ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (NASDAQ:INCY) supporting the launch of OPZELURA® Mr. Taylor to lead Palvella's U.S. sales organization in preparation for the potential U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, a serious, rare, lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. WAYNE, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Palvella Ther

    4/7/26 7:30:00 AM ET
    $ARQT
    $INCY
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch